Mtz Clinical Research Powered By Pratia
- Address
- lock Available on a paid plan
Neurology and Brain Disorders
The Clinical Unit at Mtz Clinical Research Powered By Pratia is conducting studies focused on disorders of the nervous system, aiming to test innovative treatments that improve neurological function and quality of life.
- Early Alzheimer's disease with inflammatory biomarkers
- Refractory focal onset epilepsy
- Relapsing‑remitting multiple sclerosis
- Agitation associated with dementia
Across 81 trials, 52 investigators are exploring disease‑modifying approaches for these conditions, offering patients access to cutting‑edge therapeutic options.
Oncology and Hematology
Research at the site spans solid tumors and blood cancers, evaluating novel agents that target tumor growth and improve survival outcomes.
- Advanced hepatocellular carcinoma with FGFR2b overexpression
- Relapsed or refractory B‑cell malignancies
- Higher‑risk myelodysplastic syndromes
- Paroxysmal nocturnal hemoglobinuria
The program includes combination regimens and immunotherapy strategies, reflecting a commitment to advancing cancer care in Warsaw.
Cardiovascular and Metabolic Health
The facility is engaged in trials that assess cardiovascular risk reduction and metabolic disease management, testing therapies that aim to lower events and improve metabolic parameters.
- High‑risk patients without prior myocardial infarction or stroke
- Resistant hypertension resistant to multiple drug classes
- Metabolic dysfunction‑associated steatohepatitis (MASH) with fibrosis
- Type 2 diabetes and related complications
With a strong focus on heart failure and lipid‑lowering agents, the trials support personalized cardiovascular therapy for diverse patient populations.
Autoimmune and Immune‑Mediated Diseases
Studies at the Warsaw site target conditions driven by immune dysregulation, evaluating biologics and small molecules that modulate immune pathways.
- Generalized myasthenia gravis
- Moderate‑to‑severe atopic dermatitis
- Primary Sjögren’s syndrome
- Warm autoimmune hemolytic anemia
The trials aim to reduce disease activity and improve patient‑reported outcomes, positioning the center as a hub for immune‑targeted research.
Dermatology and Skin Disorders
The clinical program includes investigations of new agents for chronic inflammatory skin conditions, seeking to achieve faster symptom relief and long‑term disease control.
- Plaque psoriasis with moderate to severe involvement
- Psoriatic arthritis
- Chronic atopic dermatitis
- Linear IgA dermatosis
By testing targeted inhibitors and biologics, the site contributes to expanding therapeutic choices for patients with difficult‑to‑treat skin diseases.
Respiratory and Infectious Diseases
Research efforts encompass viral infections and respiratory conditions, focusing on preventive vaccines and antiviral therapies to reduce disease burden.
- Respiratory syncytial virus (RSV) in adults over 60
- Human metapneumovirus
- Recurrent vulvovaginal candidiasis
- Varicella infection
These studies aim to enhance immunity and provide effective treatment options for both acute and chronic respiratory infections.
Psychiatric and Mental Health
The site’s psychiatric portfolio investigates novel interventions for mood and anxiety disorders, targeting symptom reduction and relapse prevention.
- Major depressive disorder with anhedonia
- Insomnia disorder
- Agitation in early Alzheimer's disease
- Relapse prevention in depression using adjunctive agents
By integrating pharmacologic and behavioral endpoints, the trials support a holistic approach to mental health care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 16 therapeutic areas and 15 of 96 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 94 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 38 by active trials.
lock +37 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.4trials
lock +25 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Mtz Clinical Research Powered By Pratia
lock Showing 1 of 97 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF UCB0599 IN STUDY PARTICIPANTS WITH PARKINSON’S DISEASE | UCB Biopharma | Phase II | Not Recruiting | Dec 2022 | Mar 2025 |
IMP list
lock Showing 1 of 96 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride | 3 | Unknown | 2024-01-05 | 2024-07-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.